Fucoxanthin ameliorates hyperglycemia, hyperlipidemia and insulin resistance in diabetic mice partially through IRS-1_PI3K_Akt and AMPK pathways
Fucoxanthin ameliorates hyperglycemia, hyperlipidemia and insulin resistance in diabetic mice partially through IRS-1_PI3K_Akt and AMPK pathways
复制标题
岩藻黄质部分通过 IRS-1_PI3K_Akt 和 AMPK 途径改善糖尿病小鼠的高血糖、高脂血症和胰岛素抵抗
DOI：
10.1016/j.jff.2018.07.048
复制
发表时间：
2018
影响因子：
5.6
通讯作者：
xing xia
中科院分区：
文献类型：
--
作者：
Yiping Zhang;Wen Xu;Xiaoqiang Huang;Youqin Zhao;Qiangqiang Ren;Zhuan Hong;Mingqing Huang;xing xia
岩藻黄素具有潜在的抗糖尿病活性，但其确切作用和潜在机制尚不清楚。在这项研究中，C57 BL/KsJ-db/db小鼠喂食含岩藻黄质（0.2%和0.4%，w/w）的饲料6周。结果表明，膳食岩藻黄质能显著改善db/db小鼠的糖脂代谢和胰岛素抵抗，并能预防胰腺组织学改变。此外，岩藻黄质通过调节肝脏中葡萄糖激酶和磷酸烯醇丙酮酸羧激酶mRNA的表达显著降低血糖，通过调节骨骼肌中葡萄糖转运蛋白4、糖原合成酶和糖原合成酶激酶-3 β蛋白的表达促进糖原合成，并且通过调节过氧化物酶体增殖物激活受体α，β-乙酰辅酶A羧化酶，肝脏中肉毒碱棕榈酰转移酶1和脂肪酸合成酶蛋白的表达。机制研究表明，岩藻黄素有效地调节肝脏和骨骼肌中IRS-1/PI 3 K/AKT和AMPK信号蛋白的表达。结果表明，岩藻黄素是一种潜在的治疗2型糖尿病的功能性食品或药物。
Fucoxanthin has potential anti-diabetic activities, but its precise effects and underlying mechanisms remain unclear. In this study, C57BL/KsJ-db/dbmice were fed diets containing fucoxanthin (0.2% and 0.4%, w/w) for 6 weeks. Results showed dietary fucoxanthin significantly improved glucose/lipid metabolism and insulin resistance, and prevented pancreatic histological changes indb/dbmice. Moreover, fucoxanthin markedly lowered blood glucose by regulating glucokinase and phosphoenolpyruvate carboxykinase mRNA expressions in liver, promoted glycogen synthesis by regulating glucose transporter 4, glycogen synthase and glycogen synthase kinase-3 beta protein expressions in skeletal muscle, and lowered blood lipid levels by regulating peroxisome proliferator-activated receptor alpha, p-acetyl CoA carboxylase, carnitine palmitoyltransferase 1 and fatty acid synthetase protein expressions in liver. Mechanistic studies indicated that fucoxanthin effectively regulates the expression of IRS-1/PI3K/AKT and AMPK signaling proteins in liver and skeletal muscle. All results suggested that fucoxanthin is a potential functional food or effective drug for type 2 diabetes mellitus.